이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

2026년 11월 6일 업데이트: Novartis Pharmaceuticals

재발성 다발성 경화증 환자를 대상으로 레미브루티닙과 테리플루노마이드의 효능 및 안전성을 비교한 무작위, 이중 맹검, 이중 더미, 병렬 그룹 연구, 공개 라벨 레미브루티닙으로 연장 치료

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

연구 유형

중재적

등록 (실제)

1007

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 115 28
        • Novartis Investigative Site
      • Athens, 그리스, 115 26
        • Novartis Investigative Site
      • Chaïdári, 그리스, 124 62
        • Novartis Investigative Site
      • Ioannina, 그리스, 455 00
        • Novartis Investigative Site
      • Larissa, 그리스, 411 10
        • Novartis Investigative Site
      • Thessaloniki, 그리스, 532 46
        • Novartis Investigative Site
      • Thessaloniki, 그리스, 546 36
        • Novartis Investigative Site
      • Pretoria, 남아프리카, 0041
        • Novartis Investigative Site
      • Rosebank, 남아프리카, 2196
        • Novartis Investigative Site
    • Free State
      • Bloemfontein, Free State, 남아프리카, 9301
        • Novartis Investigative Site
      • Essen, 독일, 45147
        • Novartis Investigative Site
      • Hamburg, 독일, 22179
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
        • Novartis Investigative Site
      • Campulung Muscel, 루마니아, 115100
        • Novartis Investigative Site
      • Constanța, 루마니아, 900591
        • Novartis Investigative Site
    • ROM
      • Brasov, ROM, 루마니아, 500123
        • Novartis Investigative Site
      • Constanța, ROM, 루마니아, 900123
        • Novartis Investigative Site
      • Mexico City, 멕시코, 14050
        • Novartis Investigative Site
      • Querétaro, 멕시코, 76070
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, 멕시코, 31203
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, 멕시코, 06700
        • Novartis Investigative Site
    • Arizona
      • Phoenix, Arizona, 미국, 85018
        • Ctr for Neurology and Spine
    • California
      • Hanford, California, 미국, 93230
        • Vladimir Royter MD APMC
      • Los Angeles, California, 미국, 90073
        • VA Greater LA Healthcare System
      • West Hollywood, California, 미국, 90048
        • Regina Berkovich MD PhD Inc
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • CU Anschutz Med Campus
      • Denver, Colorado, 미국, 80210
        • Colorado Neurological Research PC
    • Connecticut
      • Stamford, Connecticut, 미국, 06905
        • New England Institute for Clinical Research
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20007
        • Georgetown University Hospital
      • Washington D.C., District of Columbia, 미국, 20007
        • Georgetown University Hospital Research
    • Florida
      • Bradenton, Florida, 미국, 34209
        • Nova Clinical Research LLC
      • Gainesville, Florida, 미국, 32610
        • University of Florida
      • Hollywood, Florida, 미국, 33021
        • Memorial Healthcare System
      • Maitland, Florida, 미국, 32751
        • Neurology Associates PA
      • Miami, Florida, 미국, 33136
        • UM Department Of Neurology
      • Miami, Florida, 미국, 33133
        • Gables Neurology
      • Naples, Florida, 미국, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, 미국, 32803
        • Advent Health Orlando
      • Pembroke Pines, Florida, 미국, 33024
        • Humanity Clinical Research
      • Pensacola, Florida, 미국, 32514
        • Emerald Coast Neurology
      • Port Orange, Florida, 미국, 32127
        • Brain and Spine Institute
      • Vero Beach, Florida, 미국, 32960
        • Vero Beach Neurology
      • Winter Park, Florida, 미국, 32789
        • Conquest Research
    • Indiana
      • Merrillville, Indiana, 미국, 46410
        • Methodist Neuroscience Institute
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Hospital
    • Kentucky
      • Nicholasville, Kentucky, 미국, 40356
        • Baptist Physicians Lexington
    • Louisiana
      • New Orleans, Louisiana, 미국, 70121
        • Ochsner Clinic Foundation
    • Maryland
      • Frederick, Maryland, 미국, 21702
        • Clinre Comprehensive Neurology
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • Tufts Medical Center
    • Missouri
      • Kansas City, Missouri, 미국, 64128
        • Kansas City VA Medical Center
    • New York
      • Patchogue, New York, 미국, 11772
        • South Shore Neurologic Associates
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599-9500
        • University Of NC At Chapel Hill
      • Charlotte, North Carolina, 미국, 28210
        • Piedmont HealthCare
    • Ohio
      • Columbus, Ohio, 미국, 43235
        • The Boster Ctr for MS
      • Dayton, Ohio, 미국, 45408
        • Neurology Diagnostics Inc
    • Pennsylvania
      • Hershey, Pennsylvania, 미국, 17033
        • Penn State Hershey Medical Center
    • South Carolina
      • Greenville, South Carolina, 미국, 29605
        • Premier Neurology
      • Old Point Station, South Carolina, 미국, 29707
        • Metrolina Neurological Associates PA
    • Tennessee
      • Knoxville, Tennessee, 미국, 37922
        • Sibyl Wray MD Neurology PC
    • Texas
      • Dallas, Texas, 미국, 75231
        • Carum Research
      • El Paso, Texas, 미국, 79935
        • Med Research Inc
      • Frisco, Texas, 미국, 75035
        • Lone Star Neurology
      • San Antonio, Texas, 미국, 78258
        • Lonestar Neurology of San Antonio
      • San Antonio, Texas, 미국, 78229
        • UT Health MARC Medical Arts and Research Center
      • Sherman, Texas, 미국, 75092
        • Texas Institute for Neurological Disorders
      • Temple, Texas, 미국, 76508
        • Baylor Scott and White
    • Washington
      • Seattle, Washington, 미국, 98101
        • Virginia Mason Medical Centre
      • Seattle, Washington, 미국, 98133
        • University of Washington MS Clinic
    • West Virginia
      • Crab Orchard, West Virginia, 미국, 25827
        • Elligo Health Research
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, 미국, 53215
        • Ascension St Francis Center
      • Plovdiv, 불가리아, 4002
        • Novartis Investigative Site
      • Sofia, 불가리아, 1309
        • Novartis Investigative Site
      • Sofia, 불가리아, 1431
        • Novartis Investigative Site
      • Sofia, 불가리아, 1407
        • Novartis Investigative Site
      • São Paulo, 브라질, 01240-020
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, 브라질, 29055-450
        • Novartis Investigative Site
    • Federal District
      • Brasília, Federal District, 브라질, 70200-730
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, 브라질, 81210-310
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90430-001
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, 브라질, 90560-032
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, 브라질, 90620-130
        • Novartis Investigative Site
    • Santa Catarina
      • Joinville, Santa Catarina, 브라질, 89202-165
        • Novartis Investigative Site
      • Stockholm, 스웨덴, 102 35
        • Novartis Investigative Site
      • Lleida, 스페인, 25198
        • Novartis Investigative Site
      • Madrid, 스페인, 28040
        • Novartis Investigative Site
      • Madrid, 스페인, 28009
        • Novartis Investigative Site
      • Málaga, 스페인, 29016
        • Novartis Investigative Site
      • Seville, 스페인, 41009
        • Novartis Investigative Site
      • Valencia, 스페인, 46026
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, 스페인, 15706
        • Novartis Investigative Site
    • Araba
      • Vitoria-Gasteiz, Araba, 스페인, 01009
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08907
        • Novartis Investigative Site
    • Castille-La Mancha
      • Albacete, Castille-La Mancha, 스페인, 02006
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, 스페인, 08003
        • Novartis Investigative Site
    • La Rioja
      • Logroño, La Rioja, 스페인, 26006
        • Novartis Investigative Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • Novartis Investigative Site
      • Torrejón de Ardoz, Madrid, 스페인, 28850
        • Novartis Investigative Site
    • Principality of Asturias
      • Gijón, Principality of Asturias, 스페인, 33394
        • Novartis Investigative Site
    • Valencia
      • Valencia, Valencia, 스페인, 46017
        • Novartis Investigative Site
      • Banská Bystrica, 슬로바키아, 975 17
        • Novartis Investigative Site
      • Banská Bystrica, 슬로바키아, 974 04
        • Novartis Investigative Site
      • Bratislava, 슬로바키아, 833 05
        • Novartis Investigative Site
      • Celje, 슬로베니아, 3000
        • Novartis Investigative Site
      • Ljubljana, 슬로베니아, 1000
        • Novartis Investigative Site
    • Slovenia
      • Maribor, Slovenia, 슬로베니아, 2000
        • Novartis Investigative Site
      • Buenos Aires, 아르헨티나, C1012AAR
        • Novartis Investigative Site
      • CABA, 아르헨티나, C1181ACH
        • Novartis Investigative Site
      • Córdoba, 아르헨티나, X5004CDT
        • Novartis Investigative Site
    • Mendoza Province
      • Bombal, Mendoza Province, 아르헨티나, M5500DXO
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, S2000BZL
        • Novartis Investigative Site
      • Rosario, Santa Fe Province, 아르헨티나, S2000DSW
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel de, Tucumán Province, 아르헨티나, T4000
        • Novartis Investigative Site
      • Tallinn, 에스토니아, 11315
        • Novartis Investigative Site
      • Tartu, 에스토니아, 50406
        • Novartis Investigative Site
    • Invernesshire
      • Inverness, Invernesshire, 영국, IV2 3RE
        • Novartis Investigative Site
    • Kent
      • Canterbury, Kent, 영국, CT1 3NG
        • Novartis Investigative Site
      • Naples, 이탈리아, 80138
        • Novartis Investigative Site
    • BR
      • Brindisi, BR, 이탈리아, 72100
        • Novartis Investigative Site
    • FG
      • Foggia, FG, 이탈리아, 71122
        • Novartis Investigative Site
    • IS
      • Pozzilli, IS, 이탈리아, 86077
        • Novartis Investigative Site
    • ME
      • Messina, ME, 이탈리아, 98124
        • Novartis Investigative Site
    • MO
      • Modena, MO, 이탈리아, 41126
        • Novartis Investigative Site
    • PV
      • Pavia, PV, 이탈리아, 27100
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, 이탈리아, 10043
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, 인도, 682025
        • Novartis Investigative Site
    • Maharashtra
      • Pune, Maharashtra, 인도, 411013
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, 인도, 110060
        • Novartis Investigative Site
    • Punjab
      • Amritsar, Punjab, 인도, 143006
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, 인도, 500082
        • Novartis Investigative Site
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, 인도, 226007
        • Novartis Investigative Site
    • West Bengal
      • Kolkata, West Bengal, 인도, 700017
        • Novartis Investigative Site
      • Fukuoka, 일본, 8128582
        • Novartis Investigative Site
      • Niigata, 일본, 9518520
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 4668560
        • Novartis Investigative Site
    • Chiba
      • Chiba, Chiba, 일본, 2608677
        • Novartis Investigative Site
      • Ichihara, Chiba, 일본, 2990111
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka, Fukuoka, 일본, 8100022
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 0630005
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, 일본, 6500017
        • Novartis Investigative Site
      • Nishinomiya, Hyōgo, 일본, 663 8501
        • Novartis Investigative Site
    • Kanagawa
      • Isehara, Kanagawa, 일본, 2591193
        • Novartis Investigative Site
      • Sagamihara, Kanagawa, 일본, 2520375
        • Novartis Investigative Site
    • Kyoto
      • Kyoto, Kyoto, 일본, 6168255
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, 일본, 9838512
        • Novartis Investigative Site
    • Nara
      • Kashihara, Nara, 일본, 6348522
        • Novartis Investigative Site
    • Osaka
      • Moriguchi, Osaka, 일본, 5708507
        • Novartis Investigative Site
      • Suita, Osaka, 일본, 5650871
        • Novartis Investigative Site
    • Saitama
      • Higashi-Matsuyama, Saitama, 일본, 3550005
        • Novartis Investigative Site
    • Tokyo
      • Kodaira, Tokyo, 일본, 1878551
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, 일본, 1628666
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, 일본, 1600023
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, 일본, 1608582
        • Novartis Investigative Site
      • tabashi City, Tokyo, 일본, 1738610
        • Novartis Investigative Site
      • Beijing, 중국, 100034
        • Novartis Investigative Site
      • Shanghai, 중국, 200025
        • Novartis Investigative Site
      • Shanghai, 중국, 200040
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, 중국, 430030
        • Novartis Investigative Site
      • Wuhan, Hubei, 중국, 430060
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210029
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, 중국, 750004
        • Novartis Investigative Site
    • Shanxi
      • Taiyuan, Shanxi, 중국, 030001
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310016
        • Novartis Investigative Site
      • Hangzhou, Zhejiang, 중국, 310006
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, 중국, 325000
        • Novartis Investigative Site
      • Brno, 체코, 602 00
        • Novartis Investigative Site
      • Hradec Králové, 체코, 500 05
        • Novartis Investigative Site
      • Teplice, 체코, 415 29
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 2B7
        • Novartis Investigative Site
    • British Columbia
      • Burnaby, British Columbia, 캐나다, V5G 2X6
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 4K4
        • Novartis Investigative Site
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • Novartis Investigative Site
    • Quebec
      • Lévis, Quebec, 캐나다, G6W 0M5
        • Novartis Investigative Site
      • Montreal, Quebec, 캐나다, H4A 3T2
        • Novartis Investigative Site
      • Québec, Quebec, 캐나다, G1J 1Z4
        • Novartis Investigative Site
      • Saint-Jérôme, Quebec, 캐나다, J7Z 5T3
        • Novartis Investigative Site
      • Zagreb, 크로아티아, 10000
        • Novartis Investigative Site
    • Croatia
      • Zagreb, Croatia, 크로아티아, 10000
        • Novartis Investigative Site
    • HRV
      • Split, HRV, 크로아티아, 21000
        • Novartis Investigative Site
      • Varaždin, HRV, 크로아티아, 42000
        • Novartis Investigative Site
    • Vukovar
      • Vukovar, Vukovar, 크로아티아, 32000
        • Novartis Investigative Site
      • Konya, 터키 (Türkiye), 42130
        • Novartis Investigative Site
    • Atakum
      • Samsun, Atakum, 터키 (Türkiye), 55200
        • Novartis Investigative Site
    • Balcova
      • Izmir, Balcova, 터키 (Türkiye), 35340
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, 터키 (Türkiye), 34098
        • Novartis Investigative Site
      • Istanbul, Fatih, 터키 (Türkiye), 34093
        • Novartis Investigative Site
    • Karabaglar
      • Izmir, Karabaglar, 터키 (Türkiye), 35150
        • Novartis Investigative Site
    • Kocaeli
      • Köseköy, Kocaeli, 터키 (Türkiye), 41380
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, 터키 (Türkiye), 38039
        • Novartis Investigative Site
    • Nilufer
      • Bursa, Nilufer, 터키 (Türkiye), 16140
        • Novartis Investigative Site
    • Pendik
      • Istanbul, Pendik, 터키 (Türkiye), 34899
        • Novartis Investigative Site
    • Sancaktepe
      • Istanbul, Sancaktepe, 터키 (Türkiye), 34785
        • Novartis Investigative Site
      • Braga, 포르투갈, 4710-243
        • Novartis Investigative Site
      • Coimbra, 포르투갈, 3004-561
        • Novartis Investigative Site
      • Leiria, 포르투갈, 2410-197
        • Novartis Investigative Site
      • Lisbon, 포르투갈, 1649-035
        • Novartis Investigative Site
      • Lisbon, 포르투갈, 1169-050
        • Novartis Investigative Site
      • Matosinhos Municipality, 포르투갈, 4454-513
        • Novartis Investigative Site
      • Santa Maria da Feira, 포르투갈, 4520-211
        • Novartis Investigative Site
      • Bialystok, 폴란드, 15-704
        • Novartis Investigative Site
      • Glogow Wielkopolski, 폴란드, 36-060
        • Novartis Investigative Site
      • Katowice, 폴란드, 40-081
        • Novartis Investigative Site
      • Katowice, 폴란드, 40-571
        • Novartis Investigative Site
      • Katowice, 폴란드, 40-686
        • Novartis Investigative Site
      • Katowice, 폴란드, 40-689
        • Novartis Investigative Site
      • Lublin, 폴란드, 20-701
        • Novartis Investigative Site
      • Wroclaw, 폴란드, 51-685
        • Novartis Investigative Site
      • Zabrze, 폴란드, 41-800
        • Novartis Investigative Site
    • Poznan
      • Plewiska, Poznan, 폴란드, 62-064
        • Novartis Investigative Site
      • Guaynabo, 푸에르토 리코, 00968
        • Caribbean Center for Clinical Research Inc
      • Caen, 프랑스, 14033
        • Novartis Investigative Site
      • Clermont-Ferrand, 프랑스, 63003
        • Novartis Investigative Site
      • Dijon, 프랑스, 21000
        • Novartis Investigative Site
      • Gonesse, 프랑스, 95500
        • Novartis Investigative Site
      • Grenoble, 프랑스, 38043
        • Novartis Investigative Site
      • Lille, 프랑스, 59037
        • Novartis Investigative Site
      • Lille, 프랑스, 59000
        • Novartis Investigative Site
      • Nice, 프랑스, 06000
        • Novartis Investigative Site
      • Nîmes, 프랑스, 30029
        • Novartis Investigative Site
      • Poissy, 프랑스, 78303
        • Novartis Investigative Site
      • Toulouse, 프랑스, 31059
        • Novartis Investigative Site
    • Haute Vienne
      • Limoges, Haute Vienne, 프랑스, 87000
        • Novartis Investigative Site
    • Val De Marne
      • Toulon, Val De Marne, 프랑스, 83800
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)

  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening

  • History of clinically significant CNS disease other than MS

  • Ongoing substance abuse (drug or alcohol)

  • History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),

  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML

  • suicidal ideation or behavior

  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence

  • Participants who have had a splenectomy

  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections

  • Positive results for syphilis or tuberculosis testing

  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids

  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.

  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody

  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.

  • History of severe renal disease or creatinine level

  • Participants at risk of developing or having reactivation of hepatitis

  • Hematology parameters at screening:

    • Hemoglobin: < 10 g/dl (<100g/L)
    • Platelets: < 100000/mm3 (<100 x 109/L)
    • Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
    • White blood cells: <3 000/mm3 (<3.0 x 109/L)
    • Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
    • B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant ECG abnormalities

  • Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit

  • Use of other investigational drugs

  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,

  • History of gastrointestinal bleeding

  • Major surgery within 8 weeks prior to screening

  • History of hypersensitivity to any of the study drugs or excipients

  • Pregnant or nursing (lactating) female participants, prior to randomization

  • Women of childbearing potential not using highly effective contraception

  • Sexually active males not agreeing to use condom

  • Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study

  • Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Remibrutinib - Core

Remibrutinib tablet and matching placebo of teriflunomide capsule

tablet taken orally

다른 이름들:
  • 루064
활성 비교기: Teriflunomide - Core

Teriflunomide capsule and matching placebo remibrutinib tablet

capsule taken orally

실험적: Remibrutinib - Extension

Participants on remibrutinib in Core will continue on remibrutinib tablet

tablet taken orally

다른 이름들:
  • 루064
실험적: Remibrutinib - Extension (on teriflunomide in Core)

Participants on teriflunomide in Core will switch to remibrutinib tablet

tablet taken orally

다른 이름들:
  • 루064

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
기간: From Baseline, up to 30 months

ARR is the average number of confirmed MS relapses in a year

From Baseline, up to 30 months

2차 결과 측정

결과 측정
측정값 설명
기간
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
기간: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

Baseline up to 30 months
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
기간: Baseline up to 30 months

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Annualized rate of new or enlarging T2 lesion [Core Part]
기간: Baseline up to 30 months

Number of new/newly enlarged T2 lesions per year

Baseline up to 30 months
Neurofilament light chain (Nfl) [Core Part]
기간: Baseline up to 30 months

Neurofilament light chain (NfL) concentration in serum

Baseline up to 30 months
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
기간: Baseline up to 30 months

Average number of Gd-enhancing T1 lesions per scan

Baseline up to 30 months
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
기간: Baseline up to 30 months

Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

Baseline up to 30 months
Time to first confirmed relapse [Core Part]
기간: Baseline up to 30 months

Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

Baseline up to 30 months
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
기간: Baseline up to 30 months

Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
기간: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve

Baseline up to 30 months
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
기간: Baseline up to 30 months

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Baseline up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
기간: Baseline, up to 30 months

The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

Baseline, up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
기간: Baseline up to 30 months

The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

Baseline up to 30 months
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
기간: Baseline up to 30 months

The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

Baseline up to 30 months
Change from Baseline in T2 lesion volume [Core Part]
기간: Baseline up to 30 months

Change from baseline in total T2 lesion volume.

Baseline up to 30 months
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
기간: Baseline up to 30 months

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Baseline up to 30 months
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
기간: Baseline up to 30 months

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Baseline up to 30 months
Pharmacokinetics of remibrutinib [Core Part]
기간: Month 1, Month 6

Blood concentrations of remibrutinib

Month 1, Month 6
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
기간: Day 1 Extension up to 5 years

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Day 1 Extension up to 5 years
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
기간: Day 1 Extension up to 5 years

ARR is the average number of confirmed MS relapses in a year

Day 1 Extension up to 5 years
Annualized rate of new or enlarging T2 lesion [Extension Part]
기간: Day 1 Extension up to 5 years

Number of new/newly enlarged T2 lesions per year

Day 1 Extension up to 5 years
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
기간: Day 1 Extension up to 5 years

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Day 1 Extension up to 5 years
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
기간: Day 1 Extension up to 5 years

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Day 1 Extension up to 5 years
Neurofilament light chain (NfL) [Extension Part]
기간: Day 1 Extension up to 5 years

Neurofilament light chain (NfL) concentration in serum

Day 1 Extension up to 5 years
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
기간: Day 1 Extension up to 5 years

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Day 1 Extension up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 12월 13일

기본 완료 (실제)

2026년 7월 22일

연구 완료 (추정된)

2030년 10월 30일

연구 등록 날짜

최초 제출

2021년 12월 1일

QC 기준을 충족하는 최초 제출

2021년 12월 1일

처음 게시됨 (실제)

2021년 12월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다